Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) reported Q2 EPS of ($0.63), $0.07 worse than the analyst estimate of ($0.56). Revenue for the quarter came in at $7.3 million versus the consensus estimate of $9.36 million.

For earnings history and earnings-related data on Alnylam Pharmaceuticals, Inc. (ALNY) click here.